Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics

被引：435

作者：

Feng, Xiaojun ^{[1
]}

Sureda, Antoni ^{[2
,3
]}

Jafari, Samineh ^{[4
]}

Memariani, Zahra ^{[5
]}

Tewari, Devesh ^{[6
]}

Annunziata, Giuseppe ^{[7
]}

Barrea, Luigi ^{[8
]}

Hassan, Sherif T. S. ^{[9
]}

Smejkal, Karel ^{[9
]}

Malanik, Milan ^{[9
]}

Sychrova, Alice ^{[9
]}

Barreca, Davide ^{[10
]}

Ziberna, Lovro ^{[11
]}

Mahomoodally, Mohamad Fawzi ^{[12
]}

Zengin, Gokhan ^{[13
]}

Xu, Suowen ^{[14
]}

Nabavi, Seyed Mohammad ^{[15
]}

Shen, Ai-Zong ^{[1
]}

机构：

[1] Univ Sci & Technol China, Affiliated Hosp 1, Div Life Sci & Med, Hefei 230001, Anhui, Peoples R China

[2] Univ Balear Isl, Res Grp Community Nutr & Oxidat Stress, Palma de Mallorca, Spain

[3] Inst Salud Carlos III, CIBEROBN Physiopathol Obes & Nutr CB12 03 30038, Madrid, Spain

[4] Zanjan Univ Med Sci, Sch Pharm, Dept Pharmacognosy, Zanjan, Iran

[5] Babol Univ Med Sci, Hlth Res Inst, Tradit Med & Hist Med Sci Res Ctr, Babol Sar, Iran

[6] Lovely Profess Univ, Sch Pharmaceut Sci, Dept Pharmacognosy, Phagwara, Punjab, India

[7] Univ Naples Federico II, Dept Pharm, Naples, Italy

[8] Univ Federico II Napoli, Sez Endocrinol, Dipartimento Med Clin & Chirurg, Naples, Italy

[9] Univ Vet & Pharmaceut Sci Brno, Fac Pharm, Dept Nat Drugs, Palackeho Tr 1946-1, Brno 61242, Czech Republic

[10] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, I-98168 Messina, Italy

[11] Univ Ljubljana, Fac Med, Inst Pharmacol & Expt Toxicol, SI-1000 Ljubljana, Slovenia

[12] Univ Mauritius, Fac Sci, Dept Hlth Sci, Reduit, Mauritius

[13] Selcuk Univ, Sci Fac, Dept Biol, Konya, Turkey

[14] Univ Rochester, Sch Med & Dent, Dept Med, Aab Cardiovasc Res Inst, Rochester, NY 14642 USA

[15] Baqiyatallah Univ Med Sci, Appl Biotechnol Res Ctr, Tehran 1435916471, Iran

来源：

THERANOSTICS | 2019年 / 9卷 / 07期

关键词：

berberine; cardiovascular diseases; metabolic diseases; targets; therapeutics; ACTIVATED PROTEIN-KINASE; FATTY LIVER-DISEASE; LOW-DENSITY-LIPOPROTEIN; NF-KAPPA-B; ENDOTHELIAL PROGENITOR CELLS; ISCHEMIA-REPERFUSION INJURY; SMOOTH-MUSCLE-CELLS; RED YEAST RICE; CARDIAC ISCHEMIA/REPERFUSION INJURY; NLRP3 INFLAMMASOME ACTIVATION;

D O I：

10.7150/thno.30787

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

100103 [病原生物学]; 100218 [急诊医学];

摘要：

Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide, underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is an eminent component of traditional Chinese and Ayurvedic medicine for more than 2000 years. Recently, BBR has attracted much interest for its pharmacological actions in treating and/or managing CVMD. Recent discoveries of basic, translational and clinical studies have identified many novel molecular targets of BBR (such as AMPK, SIRT1, LDLR, PCSK9, and PTP1B) and provided novel evidences supporting the promising therapeutic potential of BBR to combat CVMD. Thus, this review provides a timely overview of the pharmacological properties and therapeutic application of BBR in CVMD, and underlines recent pharmacological advances which validate BBR as a promising lead drug against CVMD.

引用

页码：1923 / 1951

页数：29

共 394 条

[1]

In vitro biological assessment of berberis vulgaris and its active constituent, berberine: Antioxidants, anti-acetylcholinesterase, anti-diabetic and anticancer effects [J].